UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results

John Carroll With Gilead's Sovaldi elbowing Vertex's Incivek aside, Vertex is calling it quits on a once-ambitious R&D effort to keep a niche for itself in hepatitis C. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS